Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib Adjuvant Therapy in High Risk Liver Transplant Recipients With Hepatocellular Carcinoma
NCT01624285Phase 2Completed
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Nov 2012
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sorafenib in hepatocellular carcinoma (HCC), sponsored by UCLA Jonsson Comprehensive Cancer Center. Started Nov 2012; status: completed.
02
Drugs
sorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01624285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01624285.